ATG14 (also known as Barkor - Beclin 1-associated autophagy-related key regulator) is a crucial autophagy protein that plays a central role in the initiation of autophagosome formation. Originally identified in Drosophila melanogaster and subsequently characterized in mammalian systems, ATG14 is essential for the recruitment of the autophagy machinery to nascent autophagosomes [1].
The protein serves as a critical nexus between cellular stress signals and the autophagy degradation pathway, making it particularly relevant to neurodegenerative diseases where protein homeostasis is compromised. ATG14 contains multiple functional domains including a BARKOR binding domain that enables interaction with BECN1 (Beclin 1), a coiled-coil domain for protein-protein interactions, and a membrane-binding domain that targets the protein to autophagosome formation sites on various cellular membranes [10].
¶ Structure and Function
ATG14 is a 492-amino acid protein encoded by the ATG14 gene located on chromosome 14q32.3 in humans. The protein contains several key structural features:
- BARKOR domain (residues 1-100): Enables binding to BECN1 (Beclin 1), the central regulator of autophagy initiation
- Coiled-coil domain (residues 150-300): Mediates homodimerization and interactions with other autophagy proteins
- Membrane-targeting domain (residues 400-450): Contains a lipid-binding motif that localizes ATG14 to the phagophore assembly site
The protein functions as part of the class III phosphatidylinositol 3-kinase (PI3K) complex, specifically the ATG14-PI3K complex (also known as PI3KC3-C1), which generates phosphatidylinositol 3-phosphate (PI3P) on isolation membranes [1]. This PI3P production is essential for the recruitment of downstream autophagy effectors including WIPI proteins and ATG16L1 complex.
ATG14 plays a pivotal role in the early stages of autophagosome formation:
- Phagophore nucleation: ATG14, in complex with BECN1 and PIK3C3 (Vps34), initiates the formation of the phagophore (the precursor to the autophagosome) by generating PI3P at specific membrane sites [2]
- Membrane recruitment: ATG14 facilitates the recruitment of downstream ATG proteins including ATG5, ATG12, and LC3 to the expanding phagophore
- Expansion coordination: The ATG14 complex coordinates the expansion of the phagophore through the lipidation of LC3 (LC3-I to LC3-II conversion)
The protein is particularly enriched at the phagophore assembly site (PAS) and on isolation membranes emanating from the endoplasmic reticulum (ER), the primary membrane source for autophagosome biogenesis [1][2].
In Parkinson's disease (PD), ATG14 has emerged as a critical regulator of mitophagy - the selective autophagy of mitochondria. Mitochondrial dysfunction is a central pathological feature of PD, and impaired mitophagy contributes to the accumulation of damaged mitochondria in dopaminergic neurons.
Key mechanisms:
- PINK1-Parkin-ATG14 pathway: Following mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates both Parkin and ubiquitin. Activated Parkin then ubiquitinates mitochondrial proteins, creating a platform for the recruitment of autophagy receptors including p62/SQSTM1 and OPTN. ATG14 interacts with these receptors to direct damaged mitochondria to the autophagosome [9]
- Alpha-synuclein clearance: ATG14-mediated autophagy is involved in the clearance of alpha-synuclein aggregates. Mutations in SNCA (the gene encoding alpha-synuclein) that cause familial PD can impair autophagic flux, and ATG14 upregulation has been shown to enhance alpha-synuclein degradation in cellular models [3]
- Dopaminergic neuron vulnerability: The high metabolic demands and oxidative stress in dopaminergic neurons make them particularly dependent on ATG14-mediated mitophagy for mitochondrial quality control. Dysfunction of this pathway contributes to the selective vulnerability of substantia nigra pars compacta neurons in PD
Therapeutic implications:
- Small molecules that enhance ATG14 expression or function are being investigated as potential PD therapeutics
- Gene therapy approaches aiming to deliver ATG14 to the striatum and substantia nigra are in pre-clinical development
In Alzheimer's disease (AD), ATG14 dysfunction contributes to the accumulation of amyloid-beta plaques and tau neurofibrillary tangles, two hallmark pathological features of the disease.
Key mechanisms:
- Amyloid-beta clearance: ATG14-mediated autophagy participates in the clearance of extracellular amyloid-beta peptides generated from amyloid precursor protein (APP) processing. Impairment of autophagic flux leads to accumulation of amyloid-beta in autophagosomes and extracellular space [11]
- Tau degradation: ATG14 is involved in the selective autophagy of hyperphosphorylated tau. The protein interacts with tau aggregates and targets them for autophagic degradation. ATG14 dysfunction contributes to tau accumulation and propagation [4]
- Neuronal survival: ATG14 is essential for neuronal survival in the adult brain. Deletion of Atg14 in mouse neurons leads to accumulation of protein aggregates, mitochondrial dysfunction, and eventual neurodegeneration [5][6]
Therapeutic implications:
- Enhancing ATG14 function represents a promising approach to restore amyloid-beta and tau clearance in AD
- The protein's role in synaptic function and memory consolidation makes it an attractive target for maintaining cognitive function [11]
In ALS, ATG14-mediated autophagy is crucial for the clearance of mutated proteins including SOD1, TDP-43, and FUS that aggregate in motor neurons.
- SOD1 clearance: ATG14 participates in the autophagic degradation of mutant SOD1, and reduced ATG14 function correlates with faster disease progression in SOD1 mouse models
- TDP-43 pathology: TDP-43 aggregates, a hallmark of ALS, are targeted by ATG14-mediated selective autophagy. Impairment of this pathway contributes to cytoplasmic TDP-43 accumulation
- Motor neuron vulnerability: Motor neurons are particularly dependent on autophagy for protein homeostasis due to their large size and high metabolic demands
In Huntington's disease (HD), ATG14 is involved in the clearance of mutant huntingtin protein (mHTT) containing expanded polyglutamine repeats.
- mHTT degradation: ATG14-mediated selective autophagy targets mutant huntingtin for degradation. Up-regulation of ATG14 reduces mHTT aggregation and improves neuronal survival in cellular and animal models
- Mitochondrial quality control: Similar to PD, ATG14-mediated mitophagy is essential for maintaining mitochondrial health in HD, where mitochondrial dysfunction is prominent
¶ Interactions and Signaling Pathways
ATG14 interacts with several key proteins in the autophagy pathway:
| Partner |
Interaction Type |
Function |
| BECN1 (Beclin 1) |
Direct binding |
Core component of PI3K complex |
| PIK3C3 (Vps34) |
Complex formation |
Lipid kinase activity |
| PIK3R4 (p150) |
Complex formation |
Regulatory subunit |
| ATG16L1 |
Downstream effector |
Autophagosome expansion |
| LC3/ATG8 |
Downstream effector |
Autophagosome closure |
| p62/SQSTM1 |
Selective autophagy |
Cargo receptor |
ATG14 activity is regulated by multiple signaling pathways:
- mTORC1 inhibition: Nutrient deprivation and mTORC1 inhibition activate autophagy by relieving the inhibitory phosphorylation of ATG14, promoting its recruitment to the phagophore assembly site
- AMPK activation: Energy depletion activates AMPK, which directly phosphorylates ATG14 at serine residues, enhancing its activity
- Calcium signaling: ER calcium release can modulate ATG14 function, linking cellular stress responses to autophagy initiation [2]
- Ubiquitination: ATG14 can be ubiquitinated, which regulates its stability and interactions with other proteins
- ATG14 agonists: Compounds that enhance ATG14 expression or function are under investigation for neurodegenerative diseases
- mTOR inhibitors: Rapamycin and other mTOR inhibitors indirectly activate ATG14 by relieving mTOR-mediated suppression
- Calcium modulators: ER calcium modulators that enhance ATG14-mediated autophagy are being explored
- Viral vector delivery: AAV-mediated ATG14 gene delivery to specific brain regions
- CRISPR activation: CRISPR-based approaches to upregulate endogenous ATG14 expression
- ATG14 modulation combined with other autophagy enhancers (e.g., trehalose)
- ATG14-targeted therapy with mitochondrial protectants (e.g., coenzyme Q10)
¶ Research Directions and Knowledge Gaps
Key questions remain regarding ATG14 function in the nervous system:
- Cell-type specificity: How does ATG14 function differ between neuronal and glial cell types?
- Selective autophagy: What determines ATG14's specificity for different cargo types (mitochondria, protein aggregates, pathogens)?
- Aging and neurodegeneration: How does aging affect ATG14 function, and does this contribute to age-related neurodegenerative diseases?
- Therapeutic window: What is the optimal level of ATG14 modulation that provides benefit without disrupting essential cellular functions?